Justices Urged To Spurn SG’s Call To Tackle ‘Skinny Labels’

By Editorial Team

Amarin Pharma Inc. has urged the U.S. Supreme Court to reject the U.S. solicitor general’s call to hear a patent case involving generic drug “skinny labels.” The company stated that the dispute over its heart drug Vascepa deals with factual issues that are not suitable for high court review.

The case revolves around the patents related to Amarin Pharma Inc.’s heart drug Vascepa. The U.S. solicitor general has called for the Supreme Court to address the issue of “skinny labels,” which are generic drug labels that omit certain patented uses of a drug.

Amarin Pharma Inc. argues that the case involves complex factual issues that are better suited for lower courts. The company believes that the Supreme Court should not intervene in this matter.

The dispute has attracted the attention of various law firms and government agencies. Perkins Coie and Winston & Strawn are representing different parties in the case. Companies like Hikma Pharmaceuticals PLC are involved, along with government agencies such as the Food and Drug Administration and the U.S. Supreme Court.

The patents in question are 9,700,537, which relates to the composition for preventing the occurrence of cardiovascular events in multiple risk patients, and 10,568,861, which pertains to methods of reducing the risk of a cardiovascular event in a subject at risk for cardiovascular disease.